Robert Francomano Email

SVP, Chief Commercial Officer . SynOx Therapeutics

Current Roles

Employees:
27
Revenue:
$5.1M
About
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.
SynOx Therapeutics Address

Dublin, null
IE
SynOx Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.